AT13387: Phase I/II started

Astex began a 3-part, open-label, U.S. Phase I/II trial to evaluate weekly IV AT13387 for 3 weeks in a 4-week cycle in about 228 patients with anaplastic lymphoma kinase ( ALK)-positive or other potentially crizotinib-sensitive NSCLC who have been receiving crizotinib. The Phase I portion will evaluate escalating doses of AT13387 plus crizotinib to determine safety and the MTD of the combination to be used in the Phase II portion. The 2-part Phase II portion will compare the combination vs. crizotinib in patients who have not progressed on previous crizotinib treatment or in patients who progressed on previous crizotinib treatment. ...